in the use of [phthalocyaninato(2-)] copper in contact lenses.

FDA gave interested persons until November 28, 1986, to file objections or requests for a hearing. The agency received no objections or requests for a hearing on the final rule. Therefore, FDA had concluded that the final rule published in the Federal Register of October 28, 1986, should be confirmed.

List of Subjects in 21 CFR Part 74

Color additives, Cosmetics, Drugs, Medical devices.

Therefore, under the Federal Food, Drug, and Cosmetic Act (secs. 701, 706, 52 Stat. 1055–1056 as amended, 74 Stat. 399–407 as amended (21 U.S.C. 371, 376)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10), notice is given that no objections or requests for a hearing were filed in response to the October 28, 1986, final rule. Accordingly, the amendments promulgated thereby became effective November 28, 1986.

Dated: March 6, 1987.

Richard J. Ronk,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 87–5446 Filed 3–12–87; 8:45 am]

BILLING CODE 4160–01–M

21 CFR Parts 331, 332, and 357

[Docket No. 82N–0154]

Labeling of Drug Products for Over-The-Counter Human Use; Correction

AGENCY: Food and Drug Administration.

ACTION: Final rule; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting the final rule that changed its "exclusivity" policy for labeling of over-the-counter (OTC) drug products. This document indicates that specific paragraphs in 21 CFR 331.130(b), 332.30(a), and 357.250(b) where other statements describing indications for use are located. By indicating these specific paragraphs, FDA will eliminate the ambiguity associated with the use of the term "above".

FOR FURTHER INFORMATION CONTACT: William E. Gilbertson, Center for Drug and Biologics (HFN–210), Food and Drugs Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–295–8000.

SUPPLEMENTARY INFORMATION: In FR Doc. 86–9720, appearing on page 16258 in the issue of Thursday, May 1, 1986, the following corrections are made:

§ 331.30 [Corrected]

1. On page 16266, in the third column under § 331.30 *Labeling of antacid products,* paragraph (b), 14th line, "above" is corrected to read "in this paragraph (b)".

§ 332.30 [Corrected]

2. On page 16266, in the third column under § 332.30 *Labeling of antiflatulent products,* paragraph (a), 9th line, "above" is corrected to read "in this paragraph (a)".

§ 357.250 [Corrected]

3. On page 16267, in the second column under § 357.250 *Labeling of cholecystokinetic drug products,* paragraph (b), 9th line "above" is corrected to read "in this paragaph (b)".

Dated: March 5, 1987.

John M. Taylor,

Associate Commissioner for Regulatory Affairs.

[FR Doc. 87–5382 Filed 3–12–87; 8:45 am]

BILLING CODE 4160–01–M

21 CFR Part 341

[Docket No. 75N–052B]

Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use; Final Monograph for OTC Bronchodilator Drug Products; Correction

AGENCY: Food and Drug Administration.

ACTION: Final rule; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting the final rule that established conditions under which over-the-counter (OTC) bronchodilator drug products (drug products used in the symptomatic treatment of wheezing and shortness of breath of asthma) are generally recognized as safe and effective and not misbranded. This document indicates the specific paragraph in 21 CFR 341.76(b) where other statements describing indications for use are located. By indicating this specific paragraph, FDA will eliminate the ambiguity associated with the use of the term "below."

FOR FURTHER INFORMATION CONTACT: William E. Gilbertson, Center for Drugs and Biologics (HFN–210), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–295–8000.

SUPPLEMENTARY INFORMATION: In FR Doc. 86–22151, appearing on page 35326 in the issue of Thursday, October 2, 1986, the following correction is made on page 35339: In the third column under § 341.76 *Labeling of bronchodilator drug products,* paragraph (b), 8th line, "below" is corrected to read "in this paragraph (b)".

Dated: March 5, 1987.

John M. Taylor,

Associate Commissioner for Regulatory Affairs.

[FR Doc. 87–5380 Filed 3–12–87; 8:45 am]

BILLING CODE 4160–01–M

21 CFR Part 344

[Docket No. 77N–0334]

Topical Otic Drug Products for Over-the-Counter Human Use; Final Monograph; Correction

AGENCY: Food and Drug Administration.

ACTION: Final rule; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting the final rule that established conditions under which over-the-counter (OTC) topical otic drug products (drug products for the ear) are generally recognized as safe and effective and not misbranded. This document indicates the specific paragraph in 21 CFR 344.50(b) where other statements describing indications for use are located. By indicating this specific paragraph, FDA will eliminate the ambiguity associated with the use of the term "above."

FOR FURTHER INFORMATION CONTACT: William E. Gilbertson, Center for Drugs and Biologics (HFN–210), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–295–8000.

SUPPLEMENTARY INFORMATION: In FR Doc. 86–17854, appearing on page 28656 in the issue of Friday, August 8, 1986, the following correction is made on page 28661: In the second column under § 344.50 *Labeling of topical otic drug products,* paragraph (b), 10th line, "above" is corrected to read "in this paragraph (b)".

Dated: March 5, 1987.

John M. Taylor,

Associate Commissioner for Regulatory Affairs.

[FR Doc. 87–5381 Filed 3–12–87; 8:45 am]

BILLING CODE 4160–01–M

21 CFR Part 357

[Docket No. 79N–0378]

Anthelmintic Drug Products for Over-The-Counter Human Use; Final Monograph; Correction

AGENCY: Food and Drug Administration.

ACTION: Final rule; correction.